AMGN · News · 20260911N

IMDELLTRA Lung Cancer Results

AMGEN INC · 2026-09-11 · Importance 31 · Surprise 42

Amgen highlighted IMDELLTRA’s momentum after a late-stage study in small-cell lung cancer showed improved overall survival, including in combination with AstraZeneca’s Imfinzi. The results strengthen IMDELLTRA’s commercial positioning in small-cell lung cancer and support broader adoption of the oncology product. Amgen is seeking to reduce patient-monitoring requirements, which could improve treatment access and ease implementation for patients and providers.

Key facts

• Amgen's oncology drug IMDELLTRA showed improved overall survival in a Phase III study for small cell lung cancer. source
• Amgen's combination therapy of Imdelltra and AstraZeneca's Imfinzi significantly improved overall survival in a late-stage trial for small-cell lung cancer. source